Meeting
2019 ASCO Annual Meeting
mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study.
Authors
Thomas Denis Bachelot
GINECO-Centre Léon Bérard, Lyon, France
Thomas Denis Bachelot , Isabelle Treilleux , Camille Schiffler , Ivan Bieche , Mario Campone , Anne Patsouris , Monica Arnedos , Paul H. Cottu , Jean-Philippe Jacquin , Florence Dalenc , Valéry Attignon , Etienne Rouleau , Alain Morel , François Legrand , Marta Jimenez , Fabrice Andre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02444390
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1024)
DOI
10.1200/JCO.2019.37.15_suppl.1024
Abstract #
1024
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors.
First Author: Joaquim Bellmunt
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford
